Ekso Bionics Enters Material Definitive Agreement

TL;DR

EKSO signed a big deal, filing shows. Details to come.

AI Summary

Ekso Bionics Holdings, Inc. entered into a Material Definitive Agreement on August 29, 2024. The filing also includes financial statements and exhibits related to this agreement. The company is incorporated in Nevada and its principal executive offices are located in San Rafael, California.

Why It Matters

This filing indicates a significant new agreement for Ekso Bionics, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks and opportunities, the specifics of which are not detailed in this initial filing.

Key Players & Entities

• Ekso Bionics Holdings, Inc. (company) — Registrant
• August 29, 2024 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• San Rafael, California (location) — Address of Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock , $0.001 par value per share EKSO Nasdaq Capi
• $1.00 — s, priced at a public offering price of $1.00 per unit, with each unit consisting of
• $0.9990 — s, priced at a public offering price of $0.9990 per unit, with each pre-funded unit con
• $5.1 million — able by the Company, were approximately $5.1 million. Each Series A Warrant is exercisable
• $1 — at a price per share of Common Stock of $1.00, each Series B Warrant is exercisabl

Filing Documents

• ekso20240830_8k.htm (8-K) — 35KB
• ex_720140.htm (EX-1.1) — 562KB
• ex_720141.htm (EX-4.1) — 106KB
• ex_720142.htm (EX-4.2) — 114KB
• ex_720143.htm (EX-4.3) — 109KB
• 0001437749-24-028253.txt ( ) — 1253KB
• ekso-20240829.xsd (EX-101.SCH) — 3KB
• ekso-20240829_def.xml (EX-101.DEF) — 11KB
• ekso-20240829_lab.xml (EX-101.LAB) — 15KB
• ekso-20240829_pre.xml (EX-101.PRE) — 11KB
• ekso20240830_8k_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement On August 29, 2024, Ekso Bionics Holdings, Inc. (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with Craig-Hallum Capital Group LLC as underwriter (the "Underwriter"), pursuant to which the Company issued and sold, in a firm commitment underwritten public offering by the Company (the "Public Offering"), (i) 3,100,000 units, priced at a public offering price of $1.00 per unit, with each unit consisting of one share of the Company's common stock, par value $0.001 per share (the "Common Stock"), one Series A warrant to purchase one share of Common Stock at an exercise price of $1.00 per share that expires on the fifth anniversary of the date of issuance (a "Series A Warrant") and one warrant to purchase one share of Common Stock at an exercise price of $1.00 per share that expires on the first anniversary of the date of issuance (a "Series B Warrant") and (ii) 2,900,000 pre-funded units, priced at a public offering price of $0.9990 per unit, with each pre-funded unit consisting of one pre-funded warrant to purchase one share of Common Stock at an exercise price of $0.001 per share (a "Pre-Funded Warrant," and collectively with the Series A Warrants and the Series B Warrants, the "Warrants," and the Warrants, collectively with the Common Stock, the "Securities"), one Series A Warrant and one Series B Warrant. The units were not certificated and the shares of Common Stock, the Series A Warrants and the Series B Warrants comprising such units were immediately separable and were issued separately in the Public Offering. The pre-funded units were not certificated and the Pre-Funded Warrants, the Series A Warrants and the Series B Warrants comprising such pre-funded units were immediately separable and were issued separately in the Public Offering. The Securities were offered by the Company pursuant to the Registration Statement on Form S-1 (File No. 333-281081), which was initially

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Description 1.1* Underwriting Agreement dated as of August 29, 2024, by and between Ekso Bionics Holdings, Inc. and Craig-Hallum Capital Group LLC 4.1 Form of Pre-Funded Warrant 4.2 Form of Series A Warrant 4.3 Form of Series B Warrant 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Exhibits and schedules have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K and will be furnished to the Securities and Exchange Commission upon request. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EKSO BIONICS HOLDINGS, INC. By: /s/ Jerome Wong Name: Jerome Wong Title: Chief Financial Officer Dated: September 3, 2024

View Full Filing

View this 8-K filing on SEC EDGAR